Use of Sorafenib and/or Regorafenib in Hepatocellular Carcinoma (HCC) Subsequent to Another Systemic First-line Treatment
Phase of Trial: Phase II
Latest Information Update: 20 Sep 2019
Price : $35 *
At a glance
- Drugs Regorafenib (Primary) ; Sorafenib (Primary)
- Indications Liver cancer
- Focus Therapeutic Use
- Acronyms SORAGO-HCC
- Sponsors Bayer
- 18 Sep 2019 Status changed from recruiting to discontinued.
- 20 Mar 2019 Status changed from not yet recruiting to recruiting.
- 18 Feb 2019 Planned initiation date changed from 1 Feb 2019 to 28 Feb 2019.